EP2558866A4 - Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors - Google Patents

Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors

Info

Publication number: EP2558866A4
Authority: EP; European Patent Office
Prior art keywords: potentiation; combination therapy; cancer activity; pathway inhibitors; ber pathway
Prior art date: 2010-04-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP11769710.2A

Other languages

German (de)

French (fr)

Other versions

EP2558866A1 (en

EP2558866B1 (en

Inventor

Charles Theuer

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Tracon Pharmaceuticals Inc

Original Assignee

Tracon Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-04-15

Filing date

2011-04-15

Publication date

2013-11-06

2011-04-15 Application filed by Tracon Pharmaceuticals Inc filed Critical Tracon Pharmaceuticals Inc

2013-02-20 Publication of EP2558866A1 publication Critical patent/EP2558866A1/en

2013-11-06 Publication of EP2558866A4 publication Critical patent/EP2558866A4/en

2016-08-17 Application granted granted Critical

2016-08-17 Publication of EP2558866B1 publication Critical patent/EP2558866B1/en

Status Not-in-force legal-status Critical Current

2031-04-15 Anticipated expiration legal-status Critical

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EP11769710.2A 2010-04-15 2011-04-15 Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors Not-in-force EP2558866B1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US32465810P	2010-04-15	2010-04-15
PCT/US2011/032762 WO2011130689A1 (en)	2010-04-15	2011-04-15	Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors

Publications (3)

Publication Number	Publication Date
EP2558866A1 EP2558866A1 (en)	2013-02-20
EP2558866A4 true EP2558866A4 (en)	2013-11-06
EP2558866B1 EP2558866B1 (en)	2016-08-17

Family

ID=44799061

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP11769710.2A Not-in-force EP2558866B1 (en)	2010-04-15	2011-04-15	Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors

Country Status (4)

Country	Link
US (2)	US20130030237A1 (en)
EP (1)	EP2558866B1 (en)
ES (1)	ES2602475T3 (en)
WO (1)	WO2011130689A1 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0924084B1 (en)	2008-12-19	2021-12-21	Vertex Pharmaceuticals Incorporated	PYRAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THEM
AU2011253025A1 (en)	2010-05-12	2012-11-29	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
WO2011143422A1 (en)	2010-05-12	2011-11-17	Vertex Pharmaceuticals Incorporated	2 -aminopyridine derivatives useful as inhibitors of atr kinase
JP2013526538A (en)	2010-05-12	2013-06-24	バーテック�� ファーマシューティカルズインコーポレイテッド	Compounds useful as ATR kinase inhibitors
US9062008B2 (en)	2010-05-12	2015-06-23	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
US8962631B2 (en)	2010-05-12	2015-02-24	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
EP2569287B1 (en)	2010-05-12	2014-07-09	Vertex Pharmaceuticals Inc.	Compounds useful as inhibitors of atr kinase
WO2011163527A1 (en)	2010-06-23	2011-12-29	Vertex Pharmaceuticals Incorporated	Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
WO2012138938A1 (en)	2011-04-05	2012-10-11	Vertex Pharmaceuticals Incorporated	Aminopyrazine compounds useful as inhibitors of tra kinase
EP2723745A1 (en)	2011-06-22	2014-04-30	Vertex Pharmaceuticals Inc.	Compounds useful as inhibitors of atr kinase
JP2014522818A (en)	2011-06-22	2014-09-08	バーテックスファーマシューティカルズインコーポレイテッド	Compounds useful as ATR kinase inhibitors
JP2014517079A (en)	2011-06-22	2014-07-17	バーテックスファーマシューティカルズインコーポレイテッド	Compounds useful as ATR kinase inhibitors
IN2014CN02501A (en)	2011-09-30	2015-06-26	Vertex Pharma
SG10201606774UA (en)	2011-09-30	2016-10-28	Vertex Pharma	Processes for making compounds useful as inhibitors of atr kinase
WO2013049719A1 (en)	2011-09-30	2013-04-04	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
WO2013049720A1 (en)	2011-09-30	2013-04-04	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
MX2014003796A (en)	2011-09-30	2015-01-16	Vertex Pharma	Compounds useful as inhibitors of atr kinase.
EP2776422A1 (en)	2011-11-09	2014-09-17	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
US8841449B2 (en)	2011-11-09	2014-09-23	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
WO2013071093A1 (en)	2011-11-09	2013-05-16	Vertex Pharmaceuticals Incorporated	Pyrazine compounds useful as inhibitors of atr kinase
EP2776421A1 (en)	2011-11-09	2014-09-17	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
EP2776429A1 (en)	2011-11-09	2014-09-17	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
US20140044802A1 (en)	2012-04-05	2014-02-13	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase and combination therapies thereof
WO2013173428A1 (en) *	2012-05-15	2013-11-21	Abbvie Inc.	Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases
DK2904406T3 (en)	2012-10-04	2018-06-18	Vertex Pharma	METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
US8912198B2 (en)	2012-10-16	2014-12-16	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
SMT202000713T1 (en)	2012-12-07	2021-03-15	Vertex Pharma	Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases
JP2016512815A (en)	2013-03-15	2016-05-09	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Condensed pyrazolopyrimidine derivatives useful as inhibitors of ATR kinase
CN111481551B (en) *	2013-04-09	2023-06-09	伊利诺伊大学董事会	Tumor selective combination therapy
CA2912786A1 (en)	2013-05-21	2014-11-27	Dignity Health	Genetic signature of vulnerability to inhibitors of base excision repair (ber) in cancer
HUE046727T2 (en)	2013-12-06	2020-03-30	Vertex Pharma	2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
WO2015112598A2 (en)	2014-01-21	2015-07-30	The Johns Hopkins University	Therapy regimen and methods to sensitize cancer cells treated with epigenetic therapy to parp inhibitors in multiple cancers
GB201409485D0 (en)	2014-05-28	2014-07-09	Euro Celtique Sa	Pharmaceutical composition
GB201409471D0 (en)	2014-05-28	2014-07-09	Euro Celtique Sa	Pharmaceutical composition
CN107074863B (en)	2014-06-05	2019-12-03	沃泰克斯药物股份有限公司	Methods of making ATR kinase inhibitors and their different solid forms
PL3157566T3 (en)	2014-06-17	2019-10-31	Vertex Pharma	Method for treating cancer using a combination of chk1 and atr inhibitors
KR102678021B1 (en)	2015-09-30	2024-06-26	버텍스 파마슈티칼스 인코포레이티드	Pharmaceutical composition for cancer treatment comprising an ATR inhibitor, used in combination with a DNA damaging agent
US20190117663A1 (en) *	2016-04-04	2019-04-25	Case Western Reserve University	Compositions and methods for treating cancer
AU2016426574B2 (en)	2016-10-11	2023-07-13	Euro-Celtique S.A.	Hodgkin lymphoma therapy
GB201709403D0 (en)	2017-06-13	2017-07-26	Euro Celtique Sa	Compounds for treating sarcoma
GB201709402D0 (en)	2017-06-13	2017-07-26	Euro Celtique Sa	Compounds for treating t-pll
GB201709406D0 (en)	2017-06-13	2017-07-26	Euro-Cletique S A	Compounds for treating TNBC
GB201709405D0 (en) *	2017-06-13	2017-07-26	Euro Celtique Sa	Compounds for treating ovarian cancer
ES2971466T3 (en) *	2017-06-22	2024-06-05	Servier Lab	Combination of a Mcl-1 inhibitor and a standard of care treatment for hematological cancers, uses and pharmaceutical compositions thereof
WO2020128913A1 (en)	2018-12-18	2020-06-25	Mundipharma International Corporation Limited	Compounds for treating multiple myeloma
US20230338521A1 (en) *	2020-05-04	2023-10-26	Merck Sharp & Dohme Llc	Methods of treating cancer using a combination of a pd-1 antagonist, a chemoradiation therapy and a parp inhibitor
EP4196106A1 (en) *	2020-08-11	2023-06-21	Auxilla Pharmaceuticals and Research LLP	A non-aqueous suspension of anticancer agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020198264A1 (en) *	1999-08-13	2002-12-26	Case Western Reserve University	Methoxyamine combinations in the treatment of cancer

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3993073A (en)	1969-04-01	1976-11-23	Alza Corporation	Novel drug delivery device
US3598122A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3710795A (en)	1970-09-29	1973-01-16	Alza Corp	Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en)	1970-10-01	1978-01-17	Alza Corporation	Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en)	1971-06-04	1973-05-08	Alza Corp	Bandage for the controlled metering of topical drugs to the skin
US3742951A (en)	1971-08-09	1973-07-03	Alza Corp	Bandage for controlled release of vasodilators
US3996934A (en)	1971-08-09	1976-12-14	Alza Corporation	Medical bandage
BE795384A (en)	1972-02-14	1973-08-13	Ici Ltd	DRESSINGS
US3921636A (en)	1973-01-15	1975-11-25	Alza Corp	Novel drug delivery device
US3993072A (en)	1974-08-28	1976-11-23	Alza Corporation	Microporous drug delivery device
US4151273A (en)	1974-10-31	1979-04-24	The Regents Of The University Of California	Increasing the absorption rate of insoluble drugs
US3972995A (en)	1975-04-14	1976-08-03	American Home Products Corporation	Dosage form
US4077407A (en)	1975-11-24	1978-03-07	Alza Corporation	Osmotic devices having composite walls
US4031894A (en)	1975-12-08	1977-06-28	Alza Corporation	Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en)	1976-09-07	1977-11-29	Alza Corporation	Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en)	1977-07-12	1980-05-06	Alza Corporation	Therapeutic system for administering clonidine transdermally
JPS5562012A (en)	1978-11-06	1980-05-10	Teijin Ltd	Slow-releasing preparation
US4230105A (en)	1978-11-13	1980-10-28	Merck & Co., Inc.	Transdermal delivery of drugs
US4229447A (en)	1979-06-04	1980-10-21	American Home Products Corporation	Intraoral methods of using benzodiazepines
CA1146866A (en)	1979-07-05	1983-05-24	Yamanouchi Pharmaceutical Co. Ltd.	Process for the production of sustained release pharmaceutical composition of solid medical material
US4291015A (en)	1979-08-14	1981-09-22	Key Pharmaceuticals, Inc.	Polymeric diffusion matrix containing a vasodilator
US4327725A (en)	1980-11-25	1982-05-04	Alza Corporation	Osmotic device with hydrogel driving member
US5116817A (en)	1982-12-10	1992-05-26	Syntex (U.S.A.) Inc.	LHRH preparations for intranasal administration
US4476116A (en)	1982-12-10	1984-10-09	Syntex (U.S.A.) Inc.	Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US4596795A (en)	1984-04-25	1986-06-24	The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services	Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4624848A (en)	1984-05-10	1986-11-25	Ciba-Geigy Corporation	Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
GB8518301D0 (en)	1985-07-19	1985-08-29	Fujisawa Pharmaceutical Co	Hydrodynamically explosive systems
DE3684446D1 (en)	1985-12-28	1992-04-23	Sumitomo Pharma	MEDICINAL PRODUCTS WITH DELAYED RELEASED RELEASE.
US4755386A (en)	1986-01-22	1988-07-05	Schering Corporation	Buccal formulation
US5312325A (en)	1987-05-28	1994-05-17	Drug Delivery Systems Inc	Pulsating transdermal drug delivery system
US4968509A (en)	1987-07-27	1990-11-06	Mcneilab, Inc.	Oral sustained release acetaminophen formulation and process
IL92966A (en)	1989-01-12	1995-07-31	Pfizer	Dispensing devices powered by hydrogel
US5739136A (en)	1989-10-17	1998-04-14	Ellinwood, Jr.; Everett H.	Intraoral dosing method of administering medicaments
US5017381A (en)	1990-05-02	1991-05-21	Alza Corporation	Multi-unit pulsatile delivery system
US5633009A (en)	1990-11-28	1997-05-27	Sano Corporation	Transdermal administration of azapirones
AU1537292A (en)	1991-04-16	1992-11-17	Nippon Shinyaku Co. Ltd.	Method of manufacturing solid dispersion
AU661080B2 (en)	1991-11-22	1995-07-13	Warner Chilcott Company, Llc	Risedronate delayed-release compositions
US5229135A (en)	1991-11-22	1993-07-20	Prographarm Laboratories	Sustained release diltiazem formulation
US5340591A (en)	1992-01-24	1994-08-23	Fujisawa Pharmaceutical Co., Ltd.	Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5461140A (en)	1992-04-30	1995-10-24	Pharmaceutical Delivery Systems	Bioerodible polymers for solid controlled release pharmaceutical compositions
US5260068A (en)	1992-05-04	1993-11-09	Anda Sr Pharmaceuticals Inc.	Multiparticulate pulsatile drug delivery system
US5281420A (en)	1992-05-19	1994-01-25	The Procter & Gamble Company	Solid dispersion compositions of tebufelone
AU4198793A (en)	1992-07-24	1994-01-27	Takeda Chemical Industries Ltd.	Microparticle preparation and production thereof
US5700485A (en)	1992-09-10	1997-12-23	Children's Medical Center Corporation	Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
KR100291362B1 (en)	1992-10-16	2001-09-17	니뽄 신야쿠 가부시키가이샤	Preparation of wax matrix
US5260069A (en)	1992-11-27	1993-11-09	Anda Sr Pharmaceuticals Inc.	Pulsatile particles drug delivery system
US5686105A (en)	1993-10-19	1997-11-11	The Procter & Gamble Company	Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5665378A (en)	1994-09-30	1997-09-09	Davis; Roosevelt	Transdermal therapeutic formulation
US5567441A (en)	1995-03-24	1996-10-22	Andrx Pharmaceuticals Inc.	Diltiazem controlled release formulation
EP0827402A2 (en)	1995-05-17	1998-03-11	Cedars-Sinai Medical Center	Compositions containing fatty acids for improving digestion and absorption in the small intestine
SE9502244D0 (en)	1995-06-20	1995-06-20	Bioglan Ab	A composition and a process for the preparation thereof
US5837284A (en)	1995-12-04	1998-11-17	Mehta; Atul M.	Delivery of multiple doses of medications
US5858401A (en)	1996-01-22	1999-01-12	Sidmak Laboratories, Inc.	Pharmaceutical composition for cyclosporines
US6929801B2 (en)	1996-02-19	2005-08-16	Acrux Dds Pty Ltd	Transdermal delivery of antiparkinson agents
US6923983B2 (en)	1996-02-19	2005-08-02	Acrux Dds Pty Ltd	Transdermal delivery of hormones
US6458373B1 (en)	1997-01-07	2002-10-01	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
US5840329A (en)	1997-05-15	1998-11-24	Bioadvances Llc	Pulsatile drug delivery system
US6391452B1 (en)	1997-07-18	2002-05-21	Bayer Corporation	Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US5869090A (en)	1998-01-20	1999-02-09	Rosenbaum; Jerry	Transdermal delivery of dehydroepiandrosterone
US6946144B1 (en)	1998-07-08	2005-09-20	Oryxe	Transdermal delivery system
EP1027886B1 (en)	1999-02-10	2008-07-09	Pfizer Products Inc.	Pharmaceutical solid dispersions
US6395300B1 (en)	1999-05-27	2002-05-28	Acusphere, Inc.	Porous drug matrices and methods of manufacture thereof
US6465014B1 (en)	2001-03-21	2002-10-15	Isp Investments Inc.	pH-dependent sustained release, drug-delivery composition
US6960563B2 (en)	2001-08-31	2005-11-01	Morton Grove Pharmaceuticals, Inc.	Spontaneous emulsions containing cyclosporine
US20090029966A1 (en) *	2006-01-17	2009-01-29	Abbott Laboratories	Combination therapy with parp inhibitors
JP5249239B2 (en) *	2006-12-29	2013-07-31	トラコンファーマシューティカルズ，インク．	Combined antifolate metabolism in the treatment of cancer
WO2008112193A1 (en) *	2007-03-12	2008-09-18	Dana-Farber Cancer Institute	Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents
JP2011503111A (en) *	2007-11-12	2011-01-27	バイパーサイエンシズ，インコーポレイティド	Treatment of breast cancer with PARP inhibitors alone or in combination with antitumor agents

2011
- 2011-04-15 ES ES11769710.2T patent/ES2602475T3/en active Active
- 2011-04-15 EP EP11769710.2A patent/EP2558866B1/en not_active Not-in-force
- 2011-04-15 US US13/640,466 patent/US20130030237A1/en not_active Abandoned
- 2011-04-15 WO PCT/US2011/032762 patent/WO2011130689A1/en not_active Ceased
2017
- 2017-07-12 US US15/648,027 patent/US20170312233A1/en not_active Abandoned

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020198264A1 (en) *	1999-08-13	2002-12-26	Case Western Reserve University	Methoxyamine combinations in the treatment of cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BULGAR ALINA D ET AL: "Abstract n° 682: Dual inhibition of BER by TRC102 and PARP inhibitor (ABT 888) synergistically enhances cytotoxicity of TMZ in human melanoma", CANCER RESEARCH, vol. 70, no. 8, Suppl. 1, 15 April 2010 (2010-04-15), XP002712424, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/70/8_MeetingAbstracts/682> [retrieved on 20130906], DOI: 10.1158/1538-7445.AM10-682 *
J. P. PALMA ET AL: "ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors", CLINICAL CANCER RESEARCH, vol. 15, no. 23, 24 November 2009 (2009-11-24), pages 7277 - 7290, XP055078012, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-09-1245 *
PALMA JOANN P ET AL: "The PARP Inhibitor, ABT-888 Potentiates Temozolomide: Correlation with Drug Levels and Reduction in PARP Activity In Vivo", ANTICANCER RESEARCH, vol. 28, no. 5A, September 2008 (2008-09-01), pages 2625 - 2635, XP002712423, ISSN: 0250-7005 *
See also references of WO2011130689A1 *
T. J. KINSELLA: "Coordination of DNA Mismatch Repair and Base Excision Repair Processing of Chemotherapy and Radiation Damage for Targeting Resistant Cancers", CLINICAL CANCER RESEARCH, vol. 15, no. 6, 10 March 2009 (2009-03-10), pages 1853 - 1859, XP055077944, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-08-1307 *

Also Published As

Publication number	Publication date
US20170312233A1 (en)	2017-11-02
US20130030237A1 (en)	2013-01-31
EP2558866A1 (en)	2013-02-20
ES2602475T3 (en)	2017-02-21
EP2558866B1 (en)	2016-08-17
WO2011130689A1 (en)	2011-10-20

Publication	Publication Date	Title
IL222481A0 (en)	2012-12-31	Combination therapy
EP2552323A4 (en)	2013-09-25	Combination therapy
GB201004020D0 (en)	2010-04-21	New therapeutic use
AP2013007178A0 (en)	2013-10-31	BCMA-based stratification and therapy for multiplemyeloma patients
ZA201305897B (en)	2014-04-30	Combination therapy
ZA201400120B (en)	2015-09-30	Combination therapy
ZA201300967B (en)	2015-11-25	Combination anti-cancer therapy
EP2552197A4 (en)	2013-09-25	Use of copolymer for increasing activity of pesticide
PL3287131T3 (en)	2020-10-19	Therapeutic uses of ectoine
GB201011411D0 (en)	2010-08-18	Therapeutic compounds and their use
EP2701744A4 (en)	2014-08-20	Combination therapy
GB201005394D0 (en)	2010-05-12	Therapy
EP2536688A4 (en)	2014-04-02	Stable dosage forms of levomilnacipran
ZA201304079B (en)	2014-08-27	Dosages of arylsulfonamide derivatives
EP2629766A4 (en)	2014-05-14	Combination therapy
TWM388885U (en)	2010-09-21	Adjusting structure of chair back
GB201104632D0 (en)	2011-05-04	Use of medicament
TWM385982U (en)	2010-08-11	Improved structure of combination chair
TWM385287U (en)	2010-08-01	Tilting-angle-adjusting structure of chair
GB201019938D0 (en)	2011-01-05	Determination of therapeutic agents
GB201102221D0 (en)	2011-03-23	Inventions and therapy
GB201102222D0 (en)	2011-03-23	Inventions and therapy
GB201102213D0 (en)	2011-03-23	Inventions and therapy
GB201102216D0 (en)	2011-03-23	Inventions and therapy
GB201102215D0 (en)	2011-03-23	Inventions and therapy

Legal Events

Date	Code	Title	Description
2013-01-18	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2013-02-20	17P	Request for examination filed	Effective date: 20121109
2013-02-20	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2013-07-24	DAX	Request for extension of the european patent (deleted)
2013-10-16	RIC1	Information provided on ipc code assigned before grant	Ipc: G01N 33/574 20060101AFI20130912BHEP Ipc: A61P 35/00 20060101ALI20130912BHEP Ipc: A61P 35/02 20060101ALI20130912BHEP Ipc: A61K 31/137 20060101ALI20130912BHEP Ipc: A61K 45/06 20060101ALI20130912BHEP
2013-10-30	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/137 20060101ALI20130926BHEP Ipc: A61P 35/00 20060101ALI20130926BHEP Ipc: A61P 35/02 20060101ALI20130926BHEP Ipc: A61K 45/06 20060101ALI20130926BHEP Ipc: G01N 33/574 20060101AFI20130926BHEP
2013-11-06	A4	Supplementary search report drawn up and despatched	Effective date: 20131004
2014-07-16	17Q	First examination report despatched	Effective date: 20140617
2016-06-07	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2016-07-06	INTG	Intention to grant announced	Effective date: 20160608
2016-07-08	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2016-07-15	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2016-08-17	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2016-08-17	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2016-08-31	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2016-09-07	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2016-09-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: REF Ref document number: 821577 Country of ref document: AT Kind code of ref document: T Effective date: 20160915
2016-09-29	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602011029378 Country of ref document: DE
2016-11-16	REG	Reference to a national code	Ref country code: NL Ref legal event code: FP
2016-11-29	REG	Reference to a national code	Ref country code: SE Ref legal event code: TRGR
2016-12-27	REG	Reference to a national code	Ref country code: LT Ref legal event code: MG4D
2017-01-15	REG	Reference to a national code	Ref country code: AT Ref legal event code: MK05 Ref document number: 821577 Country of ref document: AT Kind code of ref document: T Effective date: 20160817
2017-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160817 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160817 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160817 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160817 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161117
2017-02-21	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2602475 Country of ref document: ES Kind code of ref document: T3 Effective date: 20170221
2017-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161118 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160817 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160817 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160817 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161219
2017-04-26	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7
2017-04-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160817 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160817
2017-05-18	REG	Reference to a national code	Ref country code: DE Ref legal event code: R097 Ref document number: 602011029378 Country of ref document: DE
2017-05-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160817 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160817 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160817 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160817 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161117 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160817
2017-06-23	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2017-06-23	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2017-07-26	26N	No opposition filed	Effective date: 20170518
2017-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160817
2018-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160817
2018-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170415
2018-04-25	REG	Reference to a national code	Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8
2018-09-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170415
2018-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160817
2019-06-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20110415
2019-10-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160817
2019-11-29	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160817
2020-03-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160817
2020-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161217
2022-06-30	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: NL Payment date: 20220426 Year of fee payment: 12
2022-07-29	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: SE Payment date: 20220427 Year of fee payment: 12 Ref country code: IT Payment date: 20220421 Year of fee payment: 12 Ref country code: IE Payment date: 20220427 Year of fee payment: 12 Ref country code: GB Payment date: 20220427 Year of fee payment: 12 Ref country code: FR Payment date: 20220425 Year of fee payment: 12 Ref country code: ES Payment date: 20220503 Year of fee payment: 12 Ref country code: DE Payment date: 20220427 Year of fee payment: 12
2022-08-31	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: CH Payment date: 20220503 Year of fee payment: 12
2023-07-12	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230529
2023-11-03	REG	Reference to a national code	Ref country code: DE Ref legal event code: R119 Ref document number: 602011029378 Country of ref document: DE
2023-11-28	REG	Reference to a national code	Ref country code: SE Ref legal event code: EUG
2023-11-30	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2023-12-06	REG	Reference to a national code	Ref country code: NL Ref legal event code: MM Effective date: 20230501
2023-12-27	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20230415
2024-01-18	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230415
2024-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230416 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230501 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230430 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230415 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230430 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231103 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230430
2024-02-14	REG	Reference to a national code	Ref country code: IE Ref legal event code: MM4A
2024-04-16	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230415
2024-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230415 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230415
2024-05-31	REG	Reference to a national code	Ref country code: ES Ref legal event code: FD2A Effective date: 20240531
2024-07-22	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230416
2024-07-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230416